Egypts Respiratory diseases drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

In Egypt, in 2016, 84% of the total number of deaths were due to NCDs, with four groups of diseases accounting for about 60% of the total death. Out of these Chronic Respiratory Diseases accounted for about 4% of the total deaths. Among the top 10 sources for DALYs in Egypt, lower respiratory infections were placed 6^th in 2019.

According to the statistics, Egyptians consumed 83 billion cigarettes in 2017-18, at a cost of 73 billion pounds ($4.6 billion), while the consumption of muassel reached 50,000 tons a year, costing 3 billion pounds ($191 million). Such extensive smoking is already known to be a risk factor for many other respiratory infections, including colds, influenza, pneumonia, and tuberculosis. This is likely to increase the demand for the respiratory disease treatment market in Egypt.



Market Drivers

The emergence of respiratory illness and other chronic diseases are driving the growth of higher-value prescription medicines in Egypt. Epidemiological studies by the WHO suggest that these diseases are the main causes of morbidity and mortality in Egypt.

Egypts evolving disease profile mirrors Western trends. One of the key drivers behind Egypts pharmaceutical market growth is the rapidly growing chronic disease burden that has accompanied the fast-growing aging population in Egypt. This age group is prone to respiratory diseases and will lead to rise in market demand for the illnesses.

A 2019 study showed that Egypt was among the top 10 countries whose population smokes all kinds of tobacco, with daily consumption of 280 million cigarettes in 2017-18. There will be a notable increase in the number of disability-adjusted life years (DALYs) for chronic diseases in Egypt from 2017 to 2030. For Chronic Respiratory Illnesses, the DALYs are expected to go up by 58%.

The effects of smoking on the respiratory system make it more likely that smokers contract these diseases, which could be more severe. Smoking is also associated with increased development of acute respiratory distress syndrome, a key complication for severe cases of COVID-19, among people with severe respiratory infections.

All these factors are eventually increasing the disease burden for respiratory illnesses in the country. The respiratory illness drug market is thus expected to grow in the coming years.